| Document |
Document Title |
|
WO/2006/087718A1 |
New compounds, inhibiting protein tyrosine kinases (PTKs) or steroid-related enzymes (SREs), which affect apoptosis in malignant tissues, and can be used in the preparation of medicaments for treating various disorders, and for elongatin...
|
|
WO/2006/082010A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein R1, R2, R2´, R3, R4, R5 and X are as defined in the specification and claims. These compounds, and the pharmaceutical compos...
|
|
WO2006055381A3 |
Disclosed are prodrugs of (2R)-2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating pati...
|
|
WO/2006/074244A2 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO2005035487A8 |
A process for reducing the levels of undesirable impurities in a mesotrione sample is disclosed, said process comprising the steps of: (i) forming a mesotrione enolate solution in an aqueous solvent, (ii) carrying out one or more purific...
|
|
WO/2006/070862A1 |
A process by which 5-deoxy-L-arabinose, which is important as a material for the production of saproterin, a useful therapeutic agent for atypical hyperphenylalaninemia, can be industrially and efficiently produced even with a simple pro...
|
|
WO/2006/068897A2 |
A premium wear resistant lubricant comprises a base stock, preferably a GTL liquid or the liquid isomerization product of slack wax or F-T wax, and a non-ionic ashless anti-wear additive. The non-ionic ashless antiwear additive is prefer...
|
|
WO/2006/066790A1 |
Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein R2 is (CR3R4)n-NR5R6 and m, p, q, Ar, R1, R3, R4, R5 and R6 are as defined in the claims, which are selective antagonists of 5-HT6 and/or 5-HT2A. Also pr...
|
|
WO2006035157A3 |
The invention relates to poly-substituted N-(benzyl)phenylacetamide-type derivatives having formula (I), pharmaceutical compositions containing same and the therapeutic use thereof as PPAR ligands, such as in the human and animal health ...
|
|
WO/2006/064054A1 |
Process for the treatment of wetwhite, wetblue or vegetable pretanned leather, characterized in that - for the purpose of said treatment - a composition containing a) 1 - 95% by weight of a product of the reaction of a phenol and a sulph...
|
|
WO/2006/062093A1 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/059149A1 |
Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO2006012603A3 |
An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analo...
|
|
WO2005097739A3 |
(Benzenesulfonyl)difluoromethyl anion, in situ generated from difluoromethyl phenyl sulfone and a base, was found to easily undergo nucleophilic substitution reactions (SN2 with primary alkyl halides, elemental halogens, and perfluoroalk...
|
|
WO/2006/048330A1 |
The invention relates to compounds of formula (I) wherein A, Y, Z1, Z2, R1 to R3 and X1 to X4 have the meaning as cited in the description and the claims. For example A is 4'-fluorobiphen-4-yl; Y is -S(O)2NH-; R1, R2 are H; X1, X2, X4 ar...
|
|
WO/2006/046593A1 |
Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted al...
|
|
WO/2006/045554A1 |
The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment o...
|
|
WO2006012227A3 |
The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...
|
|
WO2005105718A3 |
The present invention relates to a process for the preparation of compounds of formula (I), wherein the substituents are as defined in claim 1, by reacting a compound of formula (II), with a bromine or chlorine source to form a compound ...
|
|
WO/2006/043635A1 |
A novel 3-triazolylphenyl sulfide derivative which has excellent soil treatment activity when used as an insecticide/acaricide/nematicide for agricultural or horticultural plants. It is a 3-triazolylphenyl sulfide derivative represented ...
|
|
WO2006024412A3 |
Novel optically active phthalamides of the formula (I) in which A, q, R
|
|
WO/2006/041888A2 |
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...
|
|
WO/2006/040180A1 |
The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula (I) wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comp...
|
|
WO/2006/041119A1 |
Compounds represented by the general formula (1) or salts thereof, or hydrates of both, which are safe and have moderate physicochemical stability and which are useful as preventive or therapeutic agents for diseases caused by thrombus f...
|
|
WO/2006/040179A1 |
The present invention relates to aromatic compounds of the formula (I) wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals R...
|
|
WO/2006/040527A1 |
A process for making a compound of formula (I), said process comprising a) reaction of a compound of formula (II) with: i) a compound of formula (III) by nucleophilic aromatic substitution of X2 and ii) a compound of formula (IV) for exa...
|
|
WO2005007621A3 |
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...
|
|
WO/2006/035157A2 |
The invention relates to poly-substituted N-(benzyl)phenylacetamide-type derivatives having formula (I), pharmaceutical compositions containing same and the therapeutic use thereof as PPAR ligands, such as in the human and animal health ...
|
|
WO2005046854A3 |
A process for the preparation of Diphenylmethylsulfinyl derivatives of formula (I) comprising (wherein R
|
|
WO/2006/035891A1 |
Isonitriles represented by the general formula (1) and antifouling agents against the adhesion of aquatics containing the same: (1) wherein R1 is CH2X (wherein X is hydroxy, halogeno, isocyano, amino, substituted amino, or optionally sub...
|
|
WO/2006/034006A1 |
The present invention is directed to polymorphs of N-(1-cyanocyclopropyl)-3-cyclopropylmethanesulfonyl-2(R)-(2,
2,2-trifluoro-1(S)-4-fluorophenylethylamino)-propionamide, methods of using them to treat a disease mediated by cathepsin S, ...
|
|
WO2005075417A8 |
The present invention relates to new fluorosulfone compounds. These fluorosulfone compounds have utility in preventing, controlling and extinguishing fire.
|
|
WO/2006/033446A1 |
The present invention relates to a compound of the formula [I]: wherein (a), in which -Y-, R4, R5 and R6 are4 R5 each as defined in the description, etc., R1 is hydrogen, halogen, lower alkyl, hydroxy, etc., R2 is hydrogen, lower alkyl o...
|
|
WO/2006/032386A1 |
The invention relates to a lyophilisate containing N-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamid
e as an active ingredient. The preparation has a longer storage stability even at higher temperatures and can be applied as a...
|
|
WO/2006/034004A2 |
The present invention is directed to a process for preparing certain cysteine protease inhibitors.
|
|
WO/2006/030278A1 |
The present invention is directed to a process for the isolation of the enantiomeric forms of modafinil with high enantiomeric purity and high overall yields by means of a continuous chromatographic process.
|
|
WO2005121078A3 |
The invention relates to substituted cyclopentene compounds of general formula (I), to a method for the production thereof, medicaments containing said compounds, in addition to the use thereof in the production of medicaments.
|
|
WO/2006/029436A1 |
The invention relates to the compounds of the general formula (I), wherein X = -CH- or -N=, n = 0 or 1, R1 = -H, -F, -OCH3 or -COOCH3, R2 = -H or -F, R3 = -H, or R2 and R3 together represent -CH2-CH2-, R4 = -H or -OCH3, R5 = -H, -OCH3 or...
|
|
WO/2006/029532A1 |
Nitrate esters and methods for mitigating neurodegeneration, affecting neuroprotection, affecting cognition enhancement, and/or preventing or mitigating tissue and/or cellular damage in a subject are described. Neurological or cognitive ...
|
|
WO/2006/024402A1 |
The invention relates to novel salts of chiral 3-halophthalic acid derivatives of formula (I) from 3-halophthalic acid anhydrides of formula (II), amines of formula (III), a method for the production thereof, the use thereof for producin...
|
|
WO2005060692A3 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2006/024412A2 |
Novel optically active phthalamides of the formula (I) in which A, q, R1, R2, E1, E2, X, m, Y, n and Z are as defined in the description, processes for preparing these compounds and their use for controlling pests.
|
|
WO/2006/021806A1 |
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.
|
|
WO/2006/021759A1 |
The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, a...
|
|
WO2004110364A3 |
|
|
WO/2006/021805A1 |
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
|
|
WO/2006/021743A1 |
A process for selectively controlling the crystallisation of thermodynamically stable Form (1) or kinetically stable Form (2) polymorphs of mesotrione from an aqueous mesotrione solution, said method comprising adjusting the pH of the me...
|
|
WO/2006/023778A2 |
The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and...
|
|
WO/2006/022225A1 |
An optically active phthalamide derivative represented by the general formula (I): (wherein R1 and R2 each represents H or optionally substituted C1-6 alkyl or C1-6 alkoxycarbonyl; R3 represents C1-6 alkyl; A represents H, C1-6 alkyl, C3...
|
|
WO2005110980A3 |
Aryl sulfone compounds of formula (I) and (II) are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders.
|
